James Brian Windsor has bought stock on 2 days since Oct 2019

James Brian Windsor, Ph.D., is a biopharmaceutical executive and corporate insider who serves as Chief Executive Officer, President, and Director of Rein Therapeutics, Inc. (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc.( He was appointed CEO in March 2024 after having assumed the role of President in October 2023, and he is reported to be 59 years old.( As CEO, Windsor leads Rein Therapeutics’ strategic direction and operations in the pharmaceuticals and biotechnology sector, with total annual compensation of approximately $778,000, primarily in salary along with equity-based incentives, and holds a small direct equity stake in the company.(

Windsor is an active corporate insider in Rein Therapeutics. In April 2026, he participated in the company’s follow-on public offering, purchasing 25,000 shares of common stock at $1.00 per share, increasing his direct holdings to over 27,000 shares.( On May 8, 2026, he also received an option grant for 150,000 shares at an exercise price of $1.17, vesting over a five-year period through 2031, further aligning his interests with shareholders.( Earlier filings list him as President and CEO in prior roles associated with Aileron Therapeutics, Inc., indicating continuity of leadership through the company’s transition to Rein Therapeutics.( Publicly available summaries describe him as holding a Ph.D., though detailed information on his specific academic field and prior career posts is not disclosed in the referenced filings and profiles.(

Written by Perplexity from public sources.